PULSION Medical Systems SE

  • WKN: 548790
  • ISIN: DE0005487904
  • Land: Deutschland

Nachricht vom 25.05.2012 | 23:28

Pulsion Medical Systems SE: Publication according to § 26 paragraph. 1 WpHG with the objective of Europe-wide distribution


Pulsion Medical Systems SE 

25.05.2012 23:28

Dissemination of a Voting Rights Announcement, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------


On May 22, 2012, Ms Gabriele  Wittek, Deutschland has informed us according
to Article 21, Section 1 of the WpHG that via shares her Voting Rights on
Pulsion Medical Systems SE, Feldkirchen, Deutschland, have exceeded the 50%
threshold of the Voting Rights on April 02, 2012 and on that day amounted
to 52.06% (this corresponds to 4633543 Voting Rights).
According to Article 22, Section 2, WpHG, 51.86% of the Voting Rights (this
corresponds to 4615543 Voting Rights) is to be attributed to Ms Wittek from
FORUM Private Equity GmbH, FORUM European Smallcaps GmbH and Klaus Kühn,
whose voting interest in Pulsion Medical Systems SE amounts to 3% or more.
 



25.05.2012 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      Pulsion Medical Systems SE
              Hans-  Riedl-  Straße 21
              85622 Feldkirchen
              Germany
Internet:     www.pulsion.com
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------

Anleihe im Fokus

7,75% p.a. - Rendite aus Familienhand

– Zeichnungsstart: 23. Mai – Börse Frankfurt
– Zeichnung ab 1.000 Euro
– Laufzeit 5 Jahre
– WKN: A1TNA7
– 100% Rückzahlungskurs

GBC-Fokusbox

Syzygy AG: Aktie kaufen

Die nach den ersten drei Monaten des laufenden Jahres von Syzygy präsentierten Zahlen liegen im Rahmen unserer Erwartungen. Angesichts unserer unveränderten Prognosen behalten wir das bisherige Kursziel von 5 € bei und erneuern das Rating KAUFEN.

Aktueller Webcast

Allianz SE

Analysts' conference call on 1Q 2013

15. Mai 2013

Aktuelle Research-Studie

Orad Hi-Tec Systems Ltd

Original-Research: Orad Hi Tec Systems (von VEM Aktienbank AG): Kaufen

21. Mai 2013